ATE415414T1 - Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren - Google Patents

Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren

Info

Publication number
ATE415414T1
ATE415414T1 AT01983518T AT01983518T ATE415414T1 AT E415414 T1 ATE415414 T1 AT E415414T1 AT 01983518 T AT01983518 T AT 01983518T AT 01983518 T AT01983518 T AT 01983518T AT E415414 T1 ATE415414 T1 AT E415414T1
Authority
AT
Austria
Prior art keywords
vpr
hiv
mitochondrial membrane
membrane permeabilization
screening methods
Prior art date
Application number
AT01983518T
Other languages
English (en)
Inventor
Etienne Jacotot
Guido Kroemer
Bernard Roques
Lena Edelmann
Johan Hoebeke
Catherine Brenner-Jan
Anne-Sophie Belzacq
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Univ Compiegne Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient, Inst Nat Sante Rech Med, Univ Compiegne Tech filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE415414T1 publication Critical patent/ATE415414T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT01983518T 2000-09-11 2001-09-11 Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren ATE415414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23153900P 2000-09-11 2000-09-11
US23284100P 2000-09-15 2000-09-15

Publications (1)

Publication Number Publication Date
ATE415414T1 true ATE415414T1 (de) 2008-12-15

Family

ID=26925199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983518T ATE415414T1 (de) 2000-09-11 2001-09-11 Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren

Country Status (8)

Country Link
US (3) US7056735B2 (de)
EP (1) EP1370572B1 (de)
JP (1) JP2004508385A (de)
AT (1) ATE415414T1 (de)
AU (1) AU2002215004A1 (de)
CA (1) CA2421872A1 (de)
DE (1) DE60136747D1 (de)
WO (1) WO2002020570A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
FR2827866B1 (fr) 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
FR2931151A1 (fr) * 2008-05-13 2009-11-20 Pharmaleads Soc Par Actions Si Nouveaux derives d'amino-acides, leur procede de preparation et leur utilisation therapeutique
US8968336B2 (en) 2011-12-07 2015-03-03 Edwards Lifesciences Corporation Self-cinching surgical clips and delivery system
CN113289001A (zh) * 2020-12-24 2021-08-24 上海市闵行区中心医院 一种调控肿瘤细胞凋亡的Vpr蛋白N端氨基酸多肽在制备抗肿瘤药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7000898A (en) 1996-11-01 1998-05-29 Emory University Mouse lacking heart-muscle adenine nucleotide translocator protein and methods
AU6053898A (en) 1997-08-04 1999-02-22 Burnham Institute, The A cell-free system of mitochondria-dependent apoptosis, and methods of use ther eof
WO1999007845A1 (en) 1997-08-07 1999-02-18 Smithkline Beecham Laboratories Pharmaceutiques Adenosine nucleotide translocator
EP0911341A1 (de) 1997-10-23 1999-04-28 Smithkline Beecham Laboratoires Pharmaceutiques Adenin-Nukleotidtranslokator
CA2349444A1 (en) * 1998-11-03 2000-05-11 Mitokor Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
JP4531267B2 (ja) 1999-01-22 2010-08-25 ザ バーナム インスティチュート ホーミングプロアポトーシス結合体およびホーミングプロアポトーシス結合体を使用する方法
AU4204800A (en) * 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase

Also Published As

Publication number Publication date
EP1370572A2 (de) 2003-12-17
EP1370572B1 (de) 2008-11-26
AU2002215004A1 (en) 2002-03-22
US7642051B2 (en) 2010-01-05
US20060052285A1 (en) 2006-03-09
DE60136747D1 (de) 2009-01-08
WO2002020570A2 (en) 2002-03-14
CA2421872A1 (en) 2002-03-14
JP2004508385A (ja) 2004-03-18
US20040072146A1 (en) 2004-04-15
US20020068273A1 (en) 2002-06-06
US7056735B2 (en) 2006-06-06
WO2002020570A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
DK1381697T3 (da) Cirkulær probe-amplifikation (CPA) af ringformede nukleinsyremolekyler
IS2186B (is) Ísómerísk sambrædd pýrrólókarbasól og ísóindólón
DE60030281D1 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
ES2066760T3 (es) Nucleotidos de alquinilamino.
FR2810406B1 (fr) Nouveaux cryptates de terre rare peu sensibles a l'extinction de fluorescence
MX9301522A (es) Construcion de adn reconbinante de virus de la mancha necrotica impatients.
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
DE602004031372D1 (de) Nachweis von staphylococcus
ATE415414T1 (de) Mitochondrialen membrane permeabilisierung durch hiv-1 vpr und screeningsverfahren
DK0654083T3 (da) PTP-D-subfamilie af protein-tyrosin-phosphataser
TR200402517T2 (tr) HBV ilaç direnci tespit metotları
BR9910120A (pt) Compostos de espisulosina tendo atividade antitumor
ATE468408T1 (de) Selektive elution von immobilisierten multiplexierten primerverlängerungsprodukten
ATE176668T1 (de) Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
DK1140933T3 (da) Fremgangsmåde til fremstilling af N6-substituerede deaza-adenosinderivater
TR200100899T2 (tr) İnsan hepatit B virüsü DNA polimerazı için bir in vitro aktivite deneyi
EA200600560A1 (ru) Ингибиторы проникновения вируса вич
CY1109583T1 (el) Κυτοκινες θηλαστικων, αντιστοιχα αντιδραστηρια
BR0014507A (pt) Ensaio de helicase por eletroquimioluminescência
DE69723456D1 (de) 1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren
EP0850249A4 (de) Neues verfahren zum nachweis von cryptosporidium
WO2003025175A3 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
Howe Targeting Inducible Heat Shock Protein 70 in Cancer and Dengue Virus Pathogenesis with a Novel Small Molecule Inhibitor
ATE323289T1 (de) Auf tsap6-bindungspartnern beruhendes screeningverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties